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Abstract
Background: Tenofovir (TDF) is one of the most widely used antiretroviral drug. Despite the high degree of
tolerability a small percentage of patients experienced alteration in tubular function during TDF use. Intracellular
TDF disposition is regulated by ATP-binding cassette (ABC) drug efflux transporters and, a reduced transport activity
may be implicated in accumulation of TDF into the cells. The aim of our study was to assess the major
determinants of TDF associated tubular dysfunction (KTD) in a real-life setting including the usefulness of
single-nucleotide polymorphisms (SNPs) mapping into ABCC2, ABCC4 and ABCC10 genes.
Methods: We retrospectively analyzed all HIV positive patients who were followed at the Infectious Diseases Unit,
DIBIC Luigi Sacco, University of Milan from April 2013 to June 2016. All patients treated with TDF who underwent a
genotypization for the functional variants mapping in ABCC2 rs717620 (−24 C > T), ABCC4 rs1751034 (3463 A > G)
and ABCC10 rs2125739 (T > C) were evaluated. KTD was defined as the presence of urine phosphate wasting and/
or proteinuria at 24 h urine analysis.
Results: One hundred fifty-eight patients were genotyped, of which 42 (26.6%) experienced signs of KTD. No statistical
significant differences were observed among patients with or without KTD regarding age, gender, ethnicity and
comorbidities (hypertension and diabetes). The percentage of patients with KTD was higher among those with “GG”
genotype at rs1751034 of ABCC4 compared to patients without KTD [6 (14.3%) vs 4 (3.5%), p = 0.01]. No statistical
significant differences were observed regarding the distribution of ABCC2 and ABCC10 SNPs. Carriers of “G” allele in
homozygous status at rs1751034 of ABCC4 showed a significant association with KTD (Odds Ratio 4.67, 95% CI 1.25–17.
46, p = 0.02) in bivariate analysis, but this association was lost in multivariable analysis. A significant association
between bone diseases and KTD was observed (Odds Ratio 3.178, 95%CI 1.529–6.603, p = 0.002).
Conclusions: According to our results ABCC4 rs1751034 could be a genetic determinant of KTD; however validation studies
are needed for therapy personalization. Noteworthy, a strong association between bone disease and KTD was also observed.
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Background
Tenofovir disoproxil fumarate (TDF), a prodrug of
Tenofovir, is a nucleotide reverse-transcriptase inhibitor
used for the treatment of human immunodeficiency virus
type 1 (HIV-1) infection. It is widely used because of its
high potency, good safety profile, convenient once daily
dosing and relatively minimal adverse reactions [1]. After
absorption, TDF is converted to tenofovir that then is
phosphorylated intracellularly to tenofovir diphosphate,
an active analog, which inhibits HIV reverse transcriptase,
arresting the elongation of DNA chain. Tenofovir is
eliminated by renal excretion through glomerular filtration
and active tubular secretion. Although tenofovir causes a
mild degree of nephrotoxicity, several cases of Fanconi
syndrome and acute renal failure have been reported in
patients on this therapy [2, 3]. The mechanism of
tenofovir-induced kidney injury isn’t completely under-
stood. Mitochondrial damage in proximal renal tubular
cells is observed in patients with significant tenofovir
induced kidney tubular dysfunction (KTD) [4]. Further-
more, because characteristics and severity of KTD vary
among individuals, the role of host genetics seems to be
influential. Tenofovir is secreted into tubular lumen by
energy-dependent pumps, Multidrug-Resistance Proteins
2 (MRP2), MRP4 and MRP7 encoded by genes ABCC2,
ABCC4 and ABCC10, respectively [5, 6]. Therefore,
genetic variants affecting these transport activity may be
implicated in tenofovir-accumulation into the cells and in
tenofovir-KTD. Previous studies have shown that some
Single-Nucleotide Polymorphism (SNPs) into ABCC2,
ABCC4 and ABCC10 genes are associated with higher
tenofovir plasma and/or intracellular levels [7–10]. More
in details, for ABCC2 rs717620 at position −24 (−24C > T),
individual with KDT was significantly higher in CC than
CT/TT carriers and, a correlation between ABCC2 CC
(−24C > T) and a higher plasma tenofovir concentration
was also reported [6, 11]. A study by Kiser et al. observed
that patients carrying the ABCC4 3463A➔G variation had
lower renal clearance of tenofovir than those without.
Finally, two SNPs mapping in ABCC10 gene (rs9349256
and rs2125739) and their haplotype were significantly
associated with KTD [10].
The aim of this study was to investigate the major deter-
minants of TDF associated tubular dysfunction (KTD) in-
cluding the correlation between polymorphisms in ABCC2,
ABCC4 and ABCC10 genes and the tenofovir-induced
KTD in a mono-centric cohort of HIV-1 positive patients.
Methods
We performed a single centre retrospective observational
cohort study in the cohort of patients followed at the
University Infectious Disease Unit of Hospital Luigi Sacco
in Milan from April 2013 to June 2016. All patients who
had been treated with a TDF-containing antiretroviral
regimen and were referred to our out-patient clinic for the
management and prevention of antiretroviral toxicities
underwent, as part of clinical practice assessment, a geno-
typing for ABCC2 rs717620 (−24 C > T), ABCC4
rs1751034 (3463 A > G) and ABCC10 rs2125739 (T > C).
Genomic DNA was isolated from peripheral blood cells
using an automatic DNA extraction system (Maxwell® 16
System, Promega) according to the manufacturer’s instruc-
tions. All genotypes were determined by Real-Time PCR,
using a panel of LightSNiP from TIB-MolBiol (assays based
on SimpleProbe®). At the end of the amplification a melting
curve analysis was performed (LightCycler 480, Roche). All
data were collected in an electronic database. We collected
data on gender, epidemiology, race, immuno-virological
situation at the start of TDF, antiretroviral history, comor-
bidities (bone, cardiovascular, diabetes) and urine examin-
ation comprehensive of a 24 h sample. We defined KTD in
our cohort as the presence of abnormal proteinuria (24 h
urine proteins >150 mg) and/or phosphaturia (24 h urine
phosphate >1200 mg) at 24 h urine collected during the
period of treatment with TDF [12, 13]. The definition of
osteopenia and osteoporosis were based on DEXA scan
assessment: bone mineral density Z-score between −1 and
−2.5 standard deviation (SD) and below −2.5 SD, respect-
ively. Hypertension was defined as having a blood
pressure > 140/90 mmHg in two consecutive assessments
or if the patient was on antihypertensive drugs. Diabetes
was defined as having a fasting glucose level > 126 mg/dL
in two consecutive determination or if the patient was
taking antidiabetic drugs.
The aim of our study was to assess the distribution of the
different ABCC2, ABCC4 and ABCC10 genotypes in
patients treated with TDF with or without KTD. Baseline
characteristics were compared between patients with or
without KTD by using a descriptive statistical analysis (χ2 or
Fisher’s exact test for categorical variables and Mann-
Whitney test for continuous variables). Associations be-
tween genotypes and KTD were tested by univariate and
multivariate logistic regression analyses. The impact of all
variables was estimated with univariate analysis, and those
with P value < 0.20 were incorporated into multivariate
analysis. Statistical significance was defined at 2-sided P
value < 0.05. To perform statistical analysis we used the SAS
software version 9.3.
Results
Baseline characteristics of patients
One hundred fifty-eight patients were evaluated over a me-
dian follow-up time of 66 months (Inter quartile range
[IQR] 24–101), whose characteristics are shown in Table 1.
During the period of observation, KTD was observed in 42
(26.6%) patients. No statistically significant differences were
observed between patients with and without KTD regard-
ing age, gender and ethnicity [non-Caucasian patients were
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2 (4.8%) in the KTD group and 3 (2.6%) in patients without
KTD p = 0.490]. Patients with KTD have a longer previous
duration of therapy when compared with patients without
KTD [0,6 years (IQR 0.0–8.29) vs 0,0 years (IQR 0.0–3.8);
p = 0.034], accordingly KTD was present in a lower num-
ber of patients who received TDF as part of their initial
antiretroviral regimen [14 (33,3%) vs 69 (59,5%); p = 0,004].
Furthermore, the duration of the TDF-containing regimen
appeared to be longer in patients with KTD compared to
that in patients without KTD although not statistically
significant [76 months (IQR 30–110) vs 59 months (IQR
23–95); p = 0.090]. In both groups, kidney function at
baseline, evaluated through creatinine and GFR values, and
body mass index were similar. About baseline comorbidi-
ties no differences were observed between the two groups
regarding hypertension ad diabetes, while a higher preva-
lence of bone disease (osteopenia/osteoporosis) in patients
with KTD [23 patients (54.8%) vs 32 patients (27.6%);
p = 0.002] was observed.
Genotype distribution and factors associated with KTD
The distribution of the polymorphism for ABCC2, ABCC4
and ABCC10 are shown in Table 2. A significant statistical
difference was observed in the distribution of the variant in
rs1751034 of ABCC4 in patients with KTD when compared
with patients without KTD. In particular the “GG” geno-
type at the position 3463 was more prevalent in patients
with KTD [6 (14,3%) vs 4 (3.5%); p = 0.01] (Fig. 1). No stat-
istical significant differences were observed among the
ABCC2 rs 717,620 (−24 C > T) and ABCC10 rs2125739
(T > C) genotypes. As shown in Table 3, univariate analysis
shows a significant association between KTD and the pa-
tients with the genotype GG at the position 3463 of ABCC4
[Odds ratio (OR) 4.667 (IC 95% 1.247–17.464); p = 0.022].
When we considered clinical parameters a significant asso-
ciation between bone diseases and KTD was observed [OR
3.178 (IC95% 1.529–6.603); p = 0.002], while an inverse
correlation was observed between baseline HIV-RNA [OR
0.793 (IC 95% 0.677–0.929); p = 0.004] and receiving TDF
as part of the initial antiretroviral regimen [OR 0,341 (IC
95% 0.162–0.715); p = 0.004]. In the multivariable model
the association with the GG genotype was lost [OR 2.663
(IC95% 0.610–11.621); p = 0.193] whereas the association
with bone disease maintained a statistical significance [OR
3.147 (IC95% 1.361–7.279); p = 0.007]. A trend between
diabetes and KTD emerged [OR 3.670 (IC 95% 0.914–
14.740); p = 0.067] in parallel.
Discussion
We performed our study in a population setting of HIV-1
positive patients treated with TDF. The present study
showed an increased prevalence of the variant rs1751034 of
ABCC4 in HIV-1 positive patients treated with TDF mani-
festing signs of KTD; in particular an association with the
risk of KTD and ABCC4 genotype “GG” was shown in bi-
variate analysis despite we could not confirm this finding in
multivariable analysis. In vitro studies demonstrated the
involvement of ABCC4 in the luminal efflux of adefovir
and TDF in the kidney, thus justifying a decrease in the
tubular drug secretion and an intracellular accumulation of








Female (%) 34 21.5% 8 19.0% 26 22.4% 0.649
Age [yrs] median (IQR) 42 35–48 42 37–45 42 34–49 0.591
Non-Caucasian (%) 5 3.2% 2 4.8% 3 2.6% 0.490
BMI (Kg/m2) median (IQR) 22,9 20,3–25,2 23,5 20,7–25,4 22,5 20,2–25,2 0.339
TDF as part of first ARV regimen (%) 83 52,5% 14 33,3% 69 59,5% 0.004
Previous therapy duration [yrs] median (IQR) 0.0 0.0–6.1 0.6 0.0–8.2 0.0 0.0–3.8 0.034
TDF duration (months) median (IQR) 66 24–101 76 30–110 59 23–95 0.090
Use of protease inhibitors (%) 103 65.2% 26 61.9% 77 66.4% 0.602
CD4+ (cells/μL) median (IQR) 373 228–599 430 251–635 371 224–580 0.638
HIV-RNA (log cps/mL) median (IQR) 3.8 0.0–5.0 0.0 0.0–4.5 4.0 0.0–5.0 0.012
Creatinine (mg/dL) median (IQR) 0.84 0.72–0.94 0.84 0.70–0.99 0.83 0.73–0.92 0.534
GFR (MDRD equation) median (IQR) 103 89–117 106 89–118 101 89–117 0.586
HCV coinfection (%) 18 11.4% 6 14.3% 12 10.3% 0.491
Diabetes (%) 11 7.0% 5 11.9% 6 5.2% 0.142
Hypertension (%) 20 12.7% 8 19.0% 12 10.3% 0.146
Bone diseasea (%) 55 34.8% 23 54.8% 32 27.6% 0.002
Abbreviations: yrs. years, IQR Inter quartile range, cps copies, BMI body mass index, GFR glomerular filtration rate, MDRD The Modification of Diet in Renal Disease,
TDF tenofovir diproxil fumarate, ARV antiretroviral therapy; aosteopenia/osteoporosis; *p values are for χ2 or Fisher’s exact test and Mann-Whitney test
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these drugs [14–16]. The association with polymorphisms
of ABCC4, in particular 4976, and the presence of beta2
microglobulinuria in Thai HIV-1 positive patients was
previously described by Likanonsakul et al. In the same
population approximately 20% of patients manifested signs
of KTD with a median of 5.04 years on TDF (IQR 3.9–6.7)
[7]. This findings are similar with the prevalence of KTD
observed in our cohort which has also a comparable
previous period on TDF [5.5 years (IQR 2.0–8.5)]. In an-
other study the same polymorphism was associated with a
reduced exclusion of TDF, despite the plasmatic concentra-
tion of the drugs didn’t differed between different genotypes
at ABCC4 4976 [17]. In a previous study by Rodríguez-
Nóvoa et al. an association with the ABCC 4669 genotype
CC and phosphorus wasting was observed [6]. This obser-
vation could partially explain our findings due to the fact
that we used phosphate wasting as a criteria to discriminate
between patients with and without KTD. In a study in
Japanese HIV positive patients no associations was ob-
served between polymorphisms of ABCC4 and the risk of
KTD, in the same study a strong association between the
genotype CC at position −24 of ABCC2 gene was observed.
We couldn’t confirm these findings in our real life patients
setting [9]. In another large study performed by Nishijima
et al. in the same setting no association was observed
between ABCC2 (−24C > T) and major renal outcome
(>10 ml/min/1.73 m2 decrement in eGFR relative to base-
line, >25% decrement in eGFR, and eGFR <60 ml/min/
1.73 m2) related to TDF toxicities and the authors con-
cluded that such SNPs are not to be considered a risk factor
for clinical TDF-related renal dysfunction [18]. Similar find-
ings were also reported in another study in which ABCC2
haplotypes was associated with renal proximal tubulopathy
induced by TDF in HIV-1-infected patients, but no associ-
ation was observed between ABCC4 polymorphism [19].
Despite several report of association of polymorphisms of
ABCC2 and the development of KTD in patients treated
with TDF it is notable that the exact mechanism by which
these SNPs poses at risk of KTD development remains
unknown. In particular MPR2 encoded by ABCC2 doesn’t
seems to be involved in the luminal transport of TDF in
the tubular cells of the kidney [14]. In an in vitro study
TDF renal tubular transport seems to be influenced by
genetic variation of ABCC10, the authors suggested a pos-
sible implication in ABCC10 variations and the develop-
ment of ABCC10 [10]. We weren’t able to confirm the
association of ABCC10 rs2125739 and KTD in our cohort.
In our study, traditional risk factor for KTD like diabetes or
hypertension are equally distributed between the patients
with and without KTD with a general prevalence of 7% of
Fig. 1 Distribution of different genotypes at rs1751034 of ABCC4
gene in patients with or without KTD. Abbreviations: KTD = kidney
tubular disfunction; *χ2
Table 2 Distribution of different genotypes at ABCC2 rs 717,620 (−24 C > T), ABCC4 rs1751034 (3463 A > G) and ABCC10 rs2125739








ABCC2 -24 C > T, rs717620 (%)
C/C 104 65.8% 25 59.5% 79 68.1% 0.503
C/T 52 32.9% 16 38.1% 36 31.0%
T/T 2 1.3% 1 2.4% 1 0.9%
ABCC4 3463 A > G, rs1751034 (%)
A/A 92 58.2% 27 64.3% 65 56.0% 0.010
A/G 56 35.5% 9 21.4% 47 40.5%
G/G 10 6.3% 6 14.3% 4 3.5%
ABCC10 rs2125739, T > C (%)
T/T 80 50.6% 19 45.2% 61 52.6% 0.394
T/C 66 41.8% 21 50.0% 45 38.8%
C/C 12 7.6% 2 4.8% 10 8.6%
Abbreviations: KTD kidney tubular dysfunction, ABCC ATP-binding cassette; *χ2
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diabetes and 12% of hypertension. In multivariable analysis
a trend was observed with diabetes posing patients at
greater risk of developing KTD. It’s important to manage
this modifiable classic risk factors for kidney damage espe-
cially when no clear-cut results are available from basic re-
search and a lacking association remain with SNPs and
KTD [20]. We observed a significantly higher prevalence of
bone disease in patients with signs of KTD when compared
with patients without KTD (54,8 vs 27,6%; p = 0.002) and a
strong association between bone disease an KTD was also
confirmed in the multivariable analysis. As previously de-
scribed in HIV positive patients treated with TDF a strong
association was observed between KTD and a lower bone
mineral density [21, 22]. In addition the prevalence of bone
disease (osteopenia/osteoporosis) such as the prevalence of
KTD was similar to previous report by Calmy et al. [23].
Our study has several limitations, in particular the
retrospective design of the study exposed the analysis to
biases due to the lack of data that hadn’t been reported.
The single centre design reduce the applicability of our
findings to other cohorts, e.g. we have a very little pres-
ence in this study of non-Caucasian patients. Due to the
limited size of our sample, we cannot rule out that the
association of the genotype GG at ABCC4 3463 with
tubulopathy could be driven by chance. The high preva-
lence of bone disease in our population could suggest
also a channelling bias due to the selection of patients
picked out in clinical practice – roughly one third of pa-
tients who had been taking TDF – for genotypization
due to the concomitant presence of comorbidities. The
criteria used to define KTD were also subjected to limi-
tation due to the potential intervention of confounders
and lack of specificity for proximal tubular damage.
Conclusions
We observed an association between the variant rs
1,751,034 of ABCC4 and KTD in our single centre cohort
of HIV patients treated with TDF. A strong association
between bone disease and KTD was also observed. This
finding should prompt our attention on the parallel onset
of these 2 co-morbidities and the consequent effort to
manage affected subjects in a timely manner.
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Table 3 Logistic regression of factors involved in the development of KTD
Bivariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Female vs male 0,814 0,336 1974 0,650
Caucasian vs Non-Caucasian 1883 0,304 11,684 0,497
Baseline age (per yrs) 0,989 0,956 1023 0,524
BMI ≤18 vs > 18 1133 0,335 3840 0,841
TDF as part of first ARV regimen vs TDF as part of second or further ARV regimens 0,341 0,162 0,715 0,004 1040 0,195 5537 0,963
Previous therapy duration (per yrs) 1057 0,988 1131 0,110 0,948 0,854 1051 0,309
Baseline CD4 cell count (per cells/mL) 1000 0,999 1001 0,907
Baseline Plasma HIV-RNA level (per log cps/mL) 0,793 0,677 0,929 0,004 0,809 0,578 1132 0,216
HCV coinfection 1444 0,505 4131 0,493
Baseline creatinine (per mg/dL) 1999 0,138 28,861 0,611
Duration of treatment with TDF (per months) 1006 0,998 1015 0,162 0,998 0,987 1009 0,672
Use of protease inhibitors 0,823 0,396 1712 0,602
Hypertension 2039 0,769 5405 0,152 0,991 0,318 3084 0,987
Diabetes 2477 0,714 8595 0,153 3670 0,914 14,740 0,067
Bone diseasea 3178 1529 6603 0,002 3147 1361 7279 0,007
ABCC2–24 C > T (CC vs CT/TT) 0,689 0,332 1428 0,316
ABCC4 3463 A > G (GG vs AG/AA) 4667 1247 17,464 0,022 2663 0,610 11,621 0,193
ABCC10 rs2125739 T > C (CC vs TC/TT) 0,530 0,111 2525 0,425
Abbreviations: OR odds ratio, CI confidence interval, cps copies, yrs. years, BMI body mass index, KTD kidney tubular dysfunction, ABCC ATP-binding cassette, ARV
antiretroviral therapy; aosteopenia/osteoporosis; TDF tenofovir diproxil fumarate; p values are for χ2
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